Astrana Health (ASTH) Cash & Equivalents (2010 - 2026)

Astrana Health has disclosed Cash & Equivalents across 17 years of filings, most recently posting $478.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $478.4 million, up 85.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $478.4 million (up 85.05% YoY), and the FY2025 annual result was $429.5 million, up 48.89% from the prior year.
• Cash & Equivalents came in at $478.4 million for Q1 2026 at Astrana Health, up from $429.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $478.4 million in Q1 2026 to a low of $184.0 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $293.8 million (2023), against an average of $314.4 million.
• Across the five-year window, Cash & Equivalents dropped 22.78% in 2025 and jumped 85.05% in 2026, its largest moves.
• Astrana Health's Cash & Equivalents stood at $288.0 million in 2022, then increased by 2.01% to $293.8 million in 2023, then fell by 1.82% to $288.5 million in 2024, then soared by 48.89% to $429.5 million in 2025, then gained by 11.39% to $478.4 million in 2026.
• The last three Cash & Equivalents figures came in at $478.4 million (Q1 2026), $429.5 million (Q4 2025), and $462.2 million (Q3 2025), per Business Quant data.